The abstract reports that >50% of AD patients have >30 defective variants across pharmagenes, but doesn't explain how these variants interact mechanistically. Understanding these polygenic interactions is critical for optimizing personalized treatment regimens. Gap type: unexplained_observation Source paper: Pharmacogenetics of anxiety and depression in Alzheimer's disease. (2023, Pharmacogenomics, PMID:36628952)
Landscape Summary: How do >30 defective pharmagene variants per patient mechanistically interact to influence therapeutic response? is a 0.78 priority gap in pharmacogenomics. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
How do >30 defective pharmagene variants per patient mechanistically interact to influence therapeutic response? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: